Skip to main content
. Author manuscript; available in PMC: 2021 Jul 12.
Published in final edited form as: Oncogene. 2018 Aug 9;38(2):180–193. doi: 10.1038/s41388-018-0429-3

Fig. 3.

Fig. 3

Cisplatin-resistant brain metastases of A549 cells acquire SETD2 mutation and display impaired CREB activation. a Identification of SETD2 mutation by MiSeq sequencing in A549-R4 cells, using IVG. b Identification of EGFR mutation by MiSeq sequencing in A549-R4 cells. c WB analysis of the indicated proteins in the A549-R0, -R3, and -R4 cells treated with DMF (control) or cisplatin for 24 h. d Sanger sequencing confirmation of SETD2 mutation in the A549-R4 surviving clones in clonogenic assay after exposure to cisplatin (10 μM)